Tema Etfs LLC Invests $1.74 Million in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Tema Etfs LLC acquired a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 41,968 shares of the company's stock, valued at approximately $1,735,000. Tema Etfs LLC owned approximately 0.09% of Mirum Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Jones Financial Companies Lllp lifted its holdings in shares of Mirum Pharmaceuticals by 100.0% during the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock valued at $30,000 after buying an additional 357 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Mirum Pharmaceuticals during the fourth quarter valued at approximately $35,000. R Squared Ltd bought a new position in Mirum Pharmaceuticals in the fourth quarter worth approximately $69,000. AlphaQuest LLC raised its position in Mirum Pharmaceuticals by 969.6% in the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company's stock worth $76,000 after acquiring an additional 1,658 shares during the period. Finally, Summit Investment Advisors Inc. boosted its stake in shares of Mirum Pharmaceuticals by 8.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company's stock worth $172,000 after acquiring an additional 312 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on MIRM. Raymond James reaffirmed a "strong-buy" rating on shares of Mirum Pharmaceuticals in a report on Tuesday, May 13th. Robert W. Baird upped their price target on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a research report on Thursday, February 27th. JMP Securities lifted their price objective on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the company a "market outperform" rating in a research report on Friday, May 9th. Finally, HC Wainwright reiterated a "buy" rating and set a $73.00 price objective on shares of Mirum Pharmaceuticals in a research note on Monday. Ten investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $60.73.

Insider Buying and Selling

In other news, SVP Jolanda Howe sold 57,606 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $44.35, for a total value of $2,554,826.10. Following the completion of the sale, the senior vice president now directly owns 4,841 shares of the company's stock, valued at $214,698.35. This trade represents a 92.25% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Peter Radovich sold 7,879 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.21, for a total value of $348,330.59. Following the sale, the chief operating officer now owns 18,672 shares in the company, valued at $825,489.12. The trade was a 29.67% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 92,764 shares of company stock worth $4,109,161. Corporate insiders own 14.36% of the company's stock.

Mirum Pharmaceuticals Price Performance

Shares of Mirum Pharmaceuticals stock traded down $0.23 on Friday, hitting $43.82. 35,319 shares of the company traded hands, compared to its average volume of 522,038. The stock has a market capitalization of $2.17 billion, a P/E ratio of -21.65 and a beta of 0.95. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.83 and a 52 week high of $54.23. The business has a 50-day simple moving average of $42.95 and a 200 day simple moving average of $44.57. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.05. The firm had revenue of $111.59 million for the quarter, compared to the consensus estimate of $98.47 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business's quarterly revenue was up 61.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.54) EPS. Research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.